Gyroscope Therapeutics Holdings plc: Gyroscope Therapeutics Postpones Initial Public Offering
Gyroscope Therapeutics Holdings plc ( Gyroscope ), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has postponed plans for its initial public offering. In light of market conditions, we have decided to postpone our planned initial public offering, said Khurem Farooq, Chief Executive Officer. Based on the positive feedback we have received from institutional investors on the strength of our science and investigational gene therapies, we believe it s in the best interest of our existing shareholders and employees to execute our IPO in more favorable market conditions. In the meantime, we are continuing to advance our clinical program for our investigational gene therapy, GT005, as well as our earlier stage pipeline.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Gyroscope Therapeutics Postpones Initial Public Offering
May 7, 2021 GMT
LONDON (BUSINESS WIRE) May 7, 2021
Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has postponed plans for its initial public offering.
“In light of market conditions, we have decided to postpone our planned initial public offering,” said Khurem Farooq, Chief Executive Officer. “Based on the positive feedback we have received from institutional investors on the strength of our science and investigational gene therapies, we believe it’s in the best interest of our existing shareholders and employees to execute our IPO in more favorable market conditions. In the meantime, we are continuing to advance our clinical program for our investigational gene therapy, GT005, as well as our earlier stage pipeline.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Leidos completes acquisition of Gibbs & Cox
May 7, 2021 GMT
RESTON, Va., May 7, 2021 /PRNewswire/ Leidos Holdings, Inc. (NYSE: LDOS) (“Leidos”), a FORTUNE® 500 science and technology leader, today announced the completed acquisition of Gibbs & Cox, Inc. (“Gibbs & Cox”) for approximately $380 million in cash. The transaction was previously announced on Feb. 23, 2021. Gibbs & Cox will operate as a wholly-owned subsidiary and will be combined with Leidos’ maritime systems division.
Headquartered in Arlington, Virginia, Gibbs & Cox is the largest independent ship design firm focused on naval architecture and marine engineering. The company’s world class naval architects, designers, engineers and program managers develop innovative vessel designs and naval capabilities. The acquisition positions Leidos to provide a broad set of engineering solutions to the US Navy and to an expan
Tel: +44 (0) 20 3727 1000 About Syncona Syncona s purpose is to invest to extend and enhance human life. We do this by founding, building and funding a portfolio of global leaders in life science, to deliver transformational treatments to patients in areas of high unmet need. Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our strategic balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or few treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.
Share this article
Share this article
BERLIN, May 7, 2021 /PRNewswire/ Levere Holdings Corp. (NASDAQ: LVRAU) (the Company ) today announced that, commencing May 10, 2021, holders of the units sold in the Company s initial public offering of 27,128,532 units, completed on March 31, 2021, may elect to separately trade the shares of Class A common stock and redeemable warrants included in the units. Those units not separated will continue to trade on the NASDAQ Stock Market LLC ( NASDAQ ) under the symbol LVRAU, and the shares of Class A common stock and redeemable warrants that are separated will trade on NASDAQ under the symbols LVRA and LVRAW, respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company s transfer agent, in order to separate the units into shares of Class A common stock and redeemable warr